Have a feature idea you'd love to see implemented?
Let us know!
GERN Geron Corp
Price (delayed)
$3.29
Market cap
$1.99B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.32
Enterprise value
$2.01B
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two
Highlights
Geron's EPS has increased by 11% from the previous quarter and by 9% YoY
The net income has contracted by 15% YoY but it has grown by 8% from the previous quarter
GERN's debt has surged by 56% year-on-year
The quick ratio has contracted by 27% YoY and by 24% from the previous quarter
Key stats
What are the main financial stats of GERN
Market
Valuations
Earnings
Shares outstanding
604.5M
Market cap
$1.99B
Enterprise value
$2.01B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.79
Price to sales (P/S)
73.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.31
Revenue
$29.48M
Gross profit
$29.01M
Net income
-$201.19M
EBIT
-$189.07M
EBITDA
-$187.93M
Free cash flow
-$216.5M
Per share
Balance sheet
Liquidity
EPS
-$0.32
EPS diluted
-$0.32
Free cash flow per share
-$0.33
Book value per share
$0.48
Revenue per share
$0.04
TBVPS
$0.67
Total assets
$444.95M
Total liabilities
$152.67M
Debt
$87.26M
Equity
$292.28M
Working capital
$260.12M
Debt to equity
0.3
Current ratio
2.89
Quick ratio
2.69
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
-637.5%
Gross margin
98.4%
Net margin
-682.5%
Operating margin
-705.5%
Return on assets
-45.5%
Return on equity
-67.5%
Return on invested capital
-62.9%
Return on capital employed
-61.6%
Return on sales
-641.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GERN stock price
How has the Geron stock price performed over time
Intraday
-1.5%
1 week
-10.11%
1 month
-18.97%
1 year
42.42%
YTD
55.92%
QTD
-27.53%
Financial performance
How have Geron's revenue and profit performed over time
Revenue
$29.48M
Gross profit
$29.01M
Operating income
-$207.97M
Net income
-$201.19M
Gross margin
98.4%
Net margin
-682.5%
GERN's net margin has surged by 99% year-on-year and by 96% since the previous quarter
The operating margin has soared by 99% year-on-year and by 96% since the previous quarter
The net income has contracted by 15% YoY but it has grown by 8% from the previous quarter
The operating income has contracted by 15% YoY but it has grown by 9% from the previous quarter
Growth
What is Geron's growth rate over time
Valuation
What is Geron stock price valuation
P/E
N/A
P/B
6.79
P/S
73.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.31
Geron's EPS has increased by 11% from the previous quarter and by 9% YoY
The P/B is 53% above the 5-year quarterly average of 4.5
Geron's equity has decreased by 4.7% from the previous quarter
The P/S is 97% below the last 4 quarters average of 2757.9 and 96% below the 5-year quarterly average of 1692.8
Efficiency
How efficient is Geron business performance
Geron's ROS has soared by 99% YoY and by 96% from the previous quarter
The ROA has grown by 10% from the previous quarter and by 6% YoY
GERN's ROE is up by 9% since the previous quarter and by 4% year-on-year
Geron's ROIC has increased by 8% from the previous quarter but it has decreased by 6% YoY
Dividends
What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GERN.
Financial health
How did Geron financials performed over time
Geron's total assets is 191% higher than its total liabilities
The quick ratio has contracted by 27% YoY and by 24% from the previous quarter
The total liabilities rose by 25% year-on-year and by 7% since the previous quarter
GERN's debt is 70% smaller than its equity
GERN's debt to equity has soared by 58% YoY and by 7% QoQ
GERN's debt has surged by 56% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.